Discussion
To our knowledge, the VELO trial is the first phase 2 RCT in which the combination of an anti-EGFR drug (panitumumab) with a standard-of-care drug (trifluridine-tipiracil) has been evaluated as anti-EGFR rechallenge therapy for refractory These findings also support the use of pretreatment plasma ctDNA for patient selection.Whereas the polymerase chain reaction–based Idylla Biocartis platform captured only known alterations for 